• United-Guardian posted first-quarter net income of $818,902, up 46% year over year, with earnings per share rising to $0.18.
• Net sales climbed 15.8% to $2,872,222.
• Operating income increased to $642,449, while settlement income totaled $303,133 tied to a contract manufacturer shutdown that disrupted Renacidin output in late 2023.
• Management cited a 24% rise in pharmaceutical sales on higher Renacidin demand, while cosmetic ingredients sales grew 21% as Ashland Specialty Ingredients purchases increased 45%.
• Company said it is optimistic sales will continue to increase in 2026, citing resumed ASI purchasing, new distribution agreements, expansion of “natural” product lines, and efforts to boost Renacidin market penetration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United-Guardian Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080900PRIMZONEFULLFEED9716194) on May 08, 2026, and is solely responsible for the information contained therein.